¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:00~10:30 MRD(minimal residual disease) diagnostic technique in adult ALL(acute lymphoblastic leukemia)                          ÀÌÁö¼ö(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:30~11:00 MRD(minimal residual disease)-based treatment approach: real world experience Á¤Çظ²(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:10~11:40 Recent advances in immunotherapy & CAR-T in ALL(acute lymphoblastic leukemia) À±ÀçÈ£(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:40~12:10 Optimal sequencing treatment for relapsed ALL(acute lymphoblastic leukemia ) ÀÌÁöÇö(µ¿¾ÆÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:10~13:40 "Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition in ALL(acute lymphoblastic leukemia)  patients " °í¹Î¿À(¼­¿ï´ë¾à)

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:40~14:10 Recent update of antibody-based chemotherapy in newly diagnosed adult ALL(acute lymphoblastic leukemia) ¹éµ¿¿ø(°æºÏÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 14:10~14:40 CNS(central nervous system) Relapse in adult ALL(acute lymphoblastic leukemia) patients ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 15:00~15:30 "Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) " º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹À¯¹æ¾ÏÇÐȸ 2023 Ãß°èÇмú´ëȸ : 2023-10-14
´ÙÀ½±Û Á¦19ȸ Çѱ¹ÀÓ»ó½Ã°¢Àü±â»ý¸®ÇÐȸ Á¤±â½ÉÆ÷Áö¾ö : 2023-10-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20850 ±¤ÁÖ 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ (2ÀÏÂ÷) : 2024-06-22 0 4 2024-05-27
20849 ¼­¿ï ´ëÇÑÃé´ãµµÇÐȸ [¿Â¶óÀÎ] Pancreato-Biliary Summer School 2024 (PB-SS) : 2024-06-22 0 8 2024-05-27
20848 ¼­¿ï Á¦26Â÷ ¼­¿ï¾Æ»êº´¿ø È£Èí±â³»°ú ¿¬¼ö°­Á : °áÇÙ°ú ºñ°áÇÙÇ×»ê±Õ ÆóÁúȯÀÇ ÃÖ½ÅÁö°ß : 2024-06-22 0 3 2024-05-27
20847 ¼­¿ï Á¦3ȸ Severance Orthopaedic Review(¼¼ºê¶õ½º ±Ù°ñ°Ý ¿¬¼ö°­ÁÂ) : 2024-06-22 0 5 2024-05-27
20846 ¼­¿ï (¿Â¶óÀÎ)2024³â ¼­´ë¹®±¸ÀÇ»çȸ ¿Â¶óÀÎÇмú´ëȸ : 2024-06-22 0 3 2024-05-27
20845 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 2ÀÏÂ÷ : 2024-06-22 0 12 2024-05-27
20844 ´ë±¸ 2024³â Á¦ 23ȸ ´ëÇѵΰ³¾È¸é¼ºÇü¿Ü°úÇÐȸ Ãá°è½ÉÆ÷Áö¾ö : 2024-06-22 0 3 2024-05-27
20843 ¼­¿ï µ¿ÀÛ±¸ÀÇ»çȸ ÀÇÇÐ ¿¬¼ö±³À°(¸¸¼ºÁúȯ, Å»¸ð¿Í ÇǺΰü¸®, »ý¼ºÇü AI Æ®·»µå¿Í ÀÇ·á, ÀÇ·áºÐÀï) : 2024-06-22 0 5 2024-05-27
20842 ¼­¿ï (¿Â¶óÀÎ) °øȲ¹üºÒ¾ÈÀå¾Ö Ä¡·áÀÇ ½ÉÃþÀû Á¢±Ù : 2024-06-22 0 3 2024-05-27
20841 °æ±â 2024³â ´ëÇѳëÀκñ´¢ÀÇÇÐȸ Á¦7Â÷ Á¤±âÇмú´ëȸ : 2024-06-22 0 4 2024-05-27
20840 ¼­¿ï (¿Â¶óÀÎ) Á¦34Â÷ ´ëÇѼҾÆÀÓ»ó¸é¿ªÇÐȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 6 2024-05-27
20839 ´ë±¸ 2024 ´ë±¸±¤¿ª½ÃÀÇ»çȸ Ãá°èÇмú´ëȸ : 2024-06-22 0 2 2024-05-27
20838 ¼­¿ï »ï¼º¼­¿ïº´¿ø The 21th SMC STROKE SYMPOSIUM, 2024 : 2024-06-22 0 3 2024-05-27
20837 ±¤ÁÖ 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21 0 2 2024-05-27
20836 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(2ÀÏÂ÷) : 2024-06-21 0 3 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷